
Transgene Investor Relations Material
Latest events

Study Update
Transgene
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Transgene SA
Access all reports
Transgene SA is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company's core expertise lies in the design and development of therapeutic vaccines and oncolytic viruses. Transgene leverages advanced viral vector technology to create targeted treatments that aim to induce immune responses against cancer cells, either by directly attacking them or by enhancing the body's immune system to do so. Key products in its clinical-stage pipeline include TG4050, an individualized therapeutic vaccine developed using the myvac platform, and TG4001, aimed at treating HPV-positive cancers. The company also develops oncolytic viruses like BT-001 and TG6050 under its Invir.IO platform. The company is headquartered in Illkirch-Graffenstaden, France, and its shares are listed on the Euronext Paris.
Key slides for Transgene SA


H1 2024
Transgene SA


Study Update
Transgene SA
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
TNG
Country
🇫🇷 France